This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig 2CV v3.1 was used to generate the results found in this report.
-
Working with individual set: OV-TP
-
Number of patients in set: 466
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:OV-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 11
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
nnon = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | longname | codelen | nnei | nncd | nsil | nmis | nstp | nspl | nind | nnon | npat | nsite | pCV | pCL | pFN | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | TP53 | tumor protein p53 | 1889 | 21 | 0 | 2 | 254 | 39 | 41 | 53 | 387 | 383 | 175 | 3.9e-15 | 1e-05 | 1e-05 | 1e-16 | 1.8e-12 |
2 | BRCA1 | breast cancer 1, early onset | 5750 | 8 | 0 | 0 | 2 | 7 | 1 | 9 | 19 | 19 | 19 | 1e-16 | 1 | 0.18 | 1.2e-15 | 1.1e-11 |
3 | NF1 | neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) | 12120 | 0 | 0 | 0 | 7 | 6 | 2 | 11 | 26 | 24 | 26 | 4.3e-14 | 1 | 0.77 | 1.4e-12 | 8.3e-09 |
4 | RB1 | retinoblastoma 1 (including osteosarcoma) | 3704 | 0 | 0 | 0 | 5 | 4 | 2 | 4 | 15 | 15 | 15 | 2.4e-09 | 1 | 0.19 | 2.6e-08 | 0.00012 |
5 | BRCA2 | breast cancer 2, early onset | 10361 | 9 | 0 | 0 | 4 | 3 | 0 | 6 | 13 | 13 | 13 | 3.1e-08 | 1 | 0.96 | 5.7e-07 | 0.0021 |
6 | IL21R | interleukin 21 receptor | 1649 | 75 | 0 | 0 | 5 | 1 | 0 | 2 | 8 | 8 | 8 | 2e-07 | 1 | 0.74 | 3.3e-06 | 0.01 |
7 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 709 | 1000 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 2 | 0.024 | 1e-05 | 0.11 | 4e-06 | 0.01 |
8 | YSK4 | yeast Sps1/Ste20-related kinase 4 (S. cerevisiae) | 4025 | 89 | 0 | 0 | 9 | 1 | 0 | 0 | 10 | 10 | 10 | 6.8e-07 | 1 | 0.9 | 1e-05 | 0.024 |
9 | ANKRD35 | ankyrin repeat domain 35 | 3058 | 32 | 0 | 0 | 8 | 1 | 0 | 0 | 9 | 9 | 9 | 1.9e-06 | 1 | 0.32 | 0.000027 | 0.055 |
10 | C9orf171 | chromosome 9 open reading frame 171 | 989 | 137 | 0 | 0 | 4 | 0 | 0 | 1 | 5 | 5 | 5 | 0.00067 | 1 | 0.0016 | 0.000041 | 0.075 |
11 | MTA2 | metastasis associated 1 family, member 2 | 2581 | 34 | 0 | 0 | 3 | 0 | 1 | 0 | 4 | 4 | 3 | 0.00039 | 0.0087 | 0.87 | 0.000046 | 0.077 |
12 | CYP11B1 | cytochrome P450, family 11, subfamily B, polypeptide 1 | 1546 | 63 | 0 | 0 | 8 | 0 | 0 | 0 | 8 | 8 | 8 | 5.1e-06 | 1 | 0.72 | 0.000067 | 0.1 |
13 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 941 | 58 | 0 | 0 | 3 | 1 | 0 | 0 | 4 | 4 | 3 | 0.00034 | 0.021 | 0.95 | 0.000092 | 0.12 |
14 | ACBD4 | acyl-Coenzyme A binding domain containing 4 | 1092 | 18 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 3 | 3 | 8.2e-06 | 1 | 0.61 | 0.0001 | 0.12 |
15 | EFEMP1 | EGF-containing fibulin-like extracellular matrix protein 1 | 1522 | 325 | 0 | 0 | 5 | 1 | 0 | 1 | 7 | 7 | 7 | 0.000027 | 1 | 0.22 | 0.00011 | 0.12 |
16 | PODN | podocan | 2028 | 92 | 0 | 0 | 5 | 0 | 0 | 1 | 6 | 6 | 6 | 8.7e-06 | 1 | 0.81 | 0.00011 | 0.12 |
17 | TOP2A | topoisomerase (DNA) II alpha 170kDa | 4732 | 111 | 0 | 1 | 4 | 0 | 0 | 4 | 8 | 8 | 8 | 9.1e-06 | 1 | 0.63 | 0.00011 | 0.12 |
18 | NCOA3 | nuclear receptor coactivator 3 | 4389 | 3 | 0 | 1 | 3 | 0 | 0 | 2 | 5 | 5 | 5 | 0.013 | 0.008 | 0.11 | 0.00012 | 0.12 |
19 | TP53TG5 | TP53 target 5 | 893 | 54 | 0 | 0 | 2 | 1 | 0 | 0 | 3 | 3 | 2 | 0.002 | 0.0084 | 0.55 | 0.00015 | 0.14 |
20 | RPGRIP1 | retinitis pigmentosa GTPase regulator interacting protein 1 | 3955 | 70 | 0 | 1 | 6 | 0 | 1 | 0 | 7 | 7 | 7 | 0.000078 | 1 | 0.12 | 0.00016 | 0.15 |
21 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 1244 | 124 | 0 | 0 | 2 | 0 | 1 | 2 | 5 | 5 | 5 | 0.000016 | 1 | 0.5 | 0.00019 | 0.17 |
22 | RB1CC1 | RB1-inducible coiled-coil 1 | 4873 | 6 | 0 | 1 | 4 | 3 | 0 | 2 | 9 | 9 | 9 | 0.000046 | 1 | 0.32 | 0.00021 | 0.17 |
23 | LPAR3 | lysophosphatidic acid receptor 3 | 1070 | 6 | 0 | 1 | 2 | 0 | 0 | 2 | 4 | 4 | 4 | 0.000022 | 1 | 0.49 | 0.00025 | 0.2 |
24 | ADAMTS4 | ADAM metallopeptidase with thrombospondin type 1 motif, 4 | 2546 | 127 | 0 | 0 | 7 | 0 | 0 | 0 | 7 | 7 | 6 | 0.00064 | 0.041 | 0.92 | 0.00034 | 0.26 |
25 | NCF2 | neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) | 1641 | 116 | 0 | 0 | 6 | 0 | 0 | 0 | 6 | 6 | 6 | 8e-05 | 1 | 0.34 | 0.00036 | 0.26 |
26 | PGAP1 | post-GPI attachment to proteins 1 | 2873 | 42 | 0 | 1 | 6 | 0 | 0 | 1 | 7 | 7 | 6 | 0.00076 | 0.036 | 0.7 | 0.00043 | 0.3 |
27 | NADK | NAD kinase | 1385 | 19 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 1 | 0.0054 | 0.01 | 0.9 | 0.00059 | 0.39 |
28 | HYDIN | hydrocephalus inducing homolog (mouse) | 15717 | 48 | 0 | 5 | 17 | 0 | 1 | 0 | 18 | 18 | 18 | 0.00039 | 1 | 0.072 | 0.00062 | 0.39 |
29 | SAMD9L | sterile alpha motif domain containing 9-like | 4759 | 30 | 0 | 2 | 6 | 2 | 0 | 1 | 9 | 9 | 9 | 0.0003 | 1 | 0.19 | 0.00064 | 0.39 |
30 | CCDC104 | coiled-coil domain containing 104 | 1067 | 141 | 0 | 0 | 2 | 0 | 0 | 1 | 3 | 3 | 3 | 0.0022 | 1 | 0.0081 | 0.00065 | 0.39 |
31 | PKD1L1 | polycystic kidney disease 1 like 1 | 8862 | 5 | 0 | 1 | 5 | 1 | 0 | 1 | 7 | 6 | 7 | 0.046 | 1 | 0.00025 | 0.00067 | 0.39 |
32 | ACTN2 | actinin, alpha 2 | 2765 | 217 | 0 | 1 | 6 | 1 | 0 | 0 | 7 | 7 | 6 | 0.0038 | 0.047 | 0.21 | 0.00068 | 0.39 |
33 | ATP6V1C2 | ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2 | 1434 | 170 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 2 | 0.0095 | 0.0076 | 0.93 | 0.00076 | 0.42 |
34 | SMG6 | Smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans) | 4334 | 11 | 0 | 0 | 2 | 2 | 0 | 0 | 4 | 4 | 3 | 0.0061 | 0.016 | 0.59 | 0.0012 | 0.63 |
35 | CLEC4F | C-type lectin domain family 4, member F | 1796 | 159 | 0 | 0 | 7 | 0 | 0 | 0 | 7 | 7 | 7 | 0.00014 | 1 | 0.84 | 0.0013 | 0.7 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.